VIRP logo

Virbac SA Stock Price

ENXTPA:VIRP Community·€3.0b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 13 Fair Values set on narratives written by author

VIRP Share Price Performance

€0
-319.00 (-100.00%)
€412.88
Fair Value
€0
-319.00 (-100.00%)
Price €0

VIRP Community Narratives

·
Fair Value €412.88 12.0% undervalued intrinsic discount

Future R&D And Facility Expansion Will Introduce New Products In Pet Care And Pharmaceuticals

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
€412.88
12.0% undervalued intrinsic discount
Revenue
5.41% p.a.
Profit Margin
12.22%
Future PE
19.02x
Price in 2029
€475.81

Trending Discussion

Updated Narratives

VIRP logo

VIRP: Stable Margins And P/E Assumptions Will Support Future Upside Repricing

Fair Value: €412.88 12.0% undervalued intrinsic discount
6 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with proven track record.

0 Risks
3 Rewards

Virbac SA Key Details

€1.5b

Revenue

€488.0m

Cost of Revenue

€976.7m

Gross Profit

€825.8m

Other Expenses

€150.9m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Sep 17, 2026
18.01
66.68%
10.30%
22.3%
View Full Analysis

About VIRP

Founded
1968
Employees
6442
CEO
Paul Martingell
WebsiteView website
corporate.virbac.com

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric pheromone gel diffuser to soothe and reduce stress-related behaviors in dogs; Suigen Entero 3 is an inactivated vaccine aimed at preventing neonatal diarrhea in piglets caused by colibacillosis, clostridium, and rotavirus; Ursolyx soft chews formulated with ursolic acid that support muscle strength and mobility in dogs and cats; Zenifel a fogger and spray designed to reduce behaviors due to stress or undesirable behaviors in cats; Suigen PCV2 is a vaccine for porcine circovirus type 2; and Suigen Donoban is a multivalent vaccine used for the prevention of respiratory diseases in swine. It also provides a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, immunology, nutrition, petfood, and pharmaceutical products. In addition, the company serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.